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Abstract. 
Introduction: Bortezomib is a proteasome
microenvironment. Intravenous Bortezomib with or without dexamethasone, is effective and well 
tolerated in patients with relapsed/refractory multiple myeloma (MM). 
Methods: We  used  Bortezomib  withou
reactivations due to patient’s Pseudomonas aeruginosa
Fibrosis. Four 21-day cycles of Bortezomib were administrated at 1.3 mg/m
with a 10 day rest period. Treatment response and toxicity were evaluated.
Results: After four cycles of therapy the patient achieved a  very good partial response (VGPR) 
according to the IMWG response criteria, without clinically significant side effects.
Conclusions: Bortezomib can be successfully utilized for the management of this difficult disease 
situation.
Bortezomib  is  a  proteasome inhibitor  that  targets 
myeloma cell and its bone marrow micro
inhibiting the binding and the paracrine loops between 
myeloma  and  bone  stromal  cells,  as  well  as 
demonstrating anabolic effects on the bone.
Intravenous  Bortezomib  (1.3  mg/m
on  days  1,4,8  and  11  of  a  21  day  cycle),  with  or 
without dexamethasone, is effective and well tolerated 
in patients with relapsed/refractory multiple myeloma 
(MM), as demonstrated by the phase II CREST
SUMMIT
2 trials,  and  the  phase  III  APEX
Bortezomib is also effective and well tolerated as part 
of a first line regimen in untreated myeloma patients as 
established  by  the  Italian  VISTA
4
trials.  The  most  frequently  reported  extra
hematological adverse events associated with th
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Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow 
microenvironment. Intravenous Bortezomib with or without dexamethasone, is effective and well 
tolerated in patients with relapsed/refractory multiple myeloma (MM). 
We  used  Bortezomib  without  corticosteroids,  to  avoid  the  risk  of  lung  infection 
Pseudomonas aeruginosa colonization, in a MM patient with Cystic 
Bortezomib were administrated at 1.3 mg/m
day rest period. Treatment response and toxicity were evaluated.
After four cycles of therapy the patient achieved a  very good partial response (VGPR) 
according to the IMWG response criteria, without clinically significant side effects.
Bortezomib can be successfully utilized for the management of this difficult disease 
inhibitor  that  targets 
myeloma cell and its bone marrow micro-environment, 
inhibiting the binding and the paracrine loops between 
myeloma  and  bone  stromal  cells,  as  well  as 
demonstrating anabolic effects on the bone.
Intravenous  Bortezomib  (1.3  mg/m
2 administered 
on  days  1,4,8  and  11  of  a  21  day  cycle),  with  or 
without dexamethasone, is effective and well tolerated 
in patients with relapsed/refractory multiple myeloma 
(MM), as demonstrated by the phase II CREST
1 and 
trials,  and  the  phase  III  APEX
3 trial. 
Bortezomib is also effective and well tolerated as part 
of a first line regimen in untreated myeloma patients as 
and  GIMEMA
5
trials.  The  most  frequently  reported  extra-
hematological adverse events associated with the use 
of  Bortezomib  are  peripheral  neuropathy, 
gastrointestinal  events,  fatigue,  and  Varicella
virus  (VZV)  reactivation.  Acyclovir  prophylaxis  at 
400-600  mg  per  day  may  prevent  early  VZV 
reactivation.
We hereby describe a case of MM  diagnosed in a
patient  with  Cystic  Fibrosis  (CF);    our  patient  was 
treated with Bortezomib therapy without any important 
side effect. 
A 36-year-old man was admitted to our Centre in 
October 2009 with anemia (Hb 10,4 g/dl, MCV 78 fl, 
RBC  3.660.000/mm
3,  WBC  8.300/  mm
273.000/mm
3)  and  a  monoclonal  protein  (1,78  g/dl). 
The patient received a diagnosis of  CF in adult age. 
Since childhood he reported a history of persistent lung 
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inhibitor that targets myeloma cell and its bone marrow 
microenvironment. Intravenous Bortezomib with or without dexamethasone, is effective and well 
t  corticosteroids,  to  avoid  the  risk  of  lung  infection 
colonization, in a MM patient with Cystic 
Bortezomib were administrated at 1.3 mg/m
2 on days 1,4,8 and 11 
After four cycles of therapy the patient achieved a  very good partial response (VGPR) 
according to the IMWG response criteria, without clinically significant side effects.
Bortezomib can be successfully utilized for the management of this difficult disease 
of  Bortezomib  are  peripheral  neuropathy, 
gastrointestinal  events,  fatigue,  and  Varicella-Zoster 
virus  (VZV)  reactivation.  Acyclovir  prophylaxis  at 
600  mg  per  day  may  prevent  early  VZV 
We hereby describe a case of MM  diagnosed in a
patient  with  Cystic  Fibrosis  (CF);    our  patient  was 
treated with Bortezomib therapy without any important 
old man was admitted to our Centre in 
October 2009 with anemia (Hb 10,4 g/dl, MCV 78 fl, 
,  WBC  8.300/  mm
3,  platelets 
)  and  a  monoclonal  protein  (1,78  g/dl). 
The patient received a diagnosis of  CF in adult age. 
Since childhood he reported a history of persistent lung Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
infections and bronchiectasis. In 2003 a diagnosis of 
CF was made by studying the mutations of the gene 
encoding  the  CFTR  protein,  which  functions  as  a 
chloride channel within a number of epithelial tissues, 
typically involved in this disease. He showed a CFTR 
exocrine  pancreatic  insufficiency  and  fat 
malabsorption, as in 90% of adult CF patient,
6 and a 
CF-related  diabetes  (40%  of  adults)
7 treated  with 
insulin.  As  CF-related  bone  disease  he  presented 
osteoporosis,  common  in  adult  CF  patients,
8 treated 
with  calcium  and  biphosphonates.  A  CT  scan 
performed in August 2009 showed a fracture of D6 that 
was initially referred to the low bone mineral density. 
In September 2009, the patient was addressed to our 
Centre  due  to  a  presence  of    anemia  and  of  a 
monoclonal component. We confirmed the anemia (Hb 
10.4 g/dl) and  the paraproteinemia (1.9 g/dl) with total 
serum protein levels of 8.4 g/dl and albumin 4.6 g/dl. 
Immunofixation study detected a  IgA-k band in the 
serum and urinalysis was positive for the Bence Jones 
protein with 10.3 g/24h k light chains. β2 microglobulin 
was  elevated  at  4547.3  mcg/L  (normal  values  700-
3400) and the lactate dehydrogenase level was normal 
112  U/L  (135-225).  The  other  laboratory  results 
including complete blood count, electrolytes, liver and 
kidney function tests, were normal. A peripheral blood 
smear showed rouleau formation of red blood cells, but 
no  morphologically  abnormal  cell.  Bone  marrow 
aspiration and biopsy were performed and revealed a 
moderate dysplastic plasmacytosis of 60% and a mild 
hypercellular  marrow  with  a  patchy  infiltration  of 
mature  and  immature  CD138+  plasma  cells.  The 
immunohistochemical stain for λ and κ showed clusters 
of dysplastic plasma cells with monotypic k light chain 
marking. There was no evidence of lytic lesions on X-
ray  films,  but  a  CT-scan  performed  in  August  2009 
showed multiple lytic lesions at the dorsal vertebra and 
pathologic fractures. A diagnosis of MM was made and 
the patient was classified as stage IIIA and II according 
to Durie and Salmon and ISS, respectively. We decided 
to treat the patient with Bortezomib alone to avoid the 
use  of  corticosteroid  and  the  risk  of  lung  infection 
reactivations,  due  to  his  Pseudomonas  aeruginosa
colonization. Four 21-day cycles of Bortezomib were 
administrated at 1.3 mg/m
2 on days 1,4,8 and 11 with a 
10  day  rest  period.  As  antibacterial  and  antiviral 
prophylaxis the  patient received Ciprofloxacine 1000 
mg and Acyclovir 600 mg daily. He had no significant 
adverse  events  during  the  treatment.  A  re-evaluation 
carried  out  in  February  2010,  after  four  cycles  of 
therapy, showed a disappearance of the M protein in 
the serum and urine, the presence of an abnormal IgA-
k band in  the  serum immunofixation analysis, and a 
concomitant decrease of bone marrow plasma cells to 
7%.  This  met  the  definition  of  a  very  good  partial 
response  (VGPR)  according  to  the  IMWG  response 
criteria.
9 Based on these results, the patient was treated 
with  subcutaneous  G-CSF    (600  mcg  per  day)  to 
mobilize  his  hematopoietic  stem  cells  that  were 
successfully  collected  from  his  peripheral  blood  by 
leukoapheresis with a yield of 10 x 10
6 CD34+ cells 
per kilogram of body weight. Based on the excellent 
response and on his past medical history, we decided to 
delay  the  autologous  stem  cell  transplantation 
eventually at the time of relapse. To date, the patient is 
maintaining  his  response  after  a  follow-up  of  13  
months.
MM  is  a  B-cell  malignancy  characterized  by  the 
expansion  of  malignant  plasma  cells  in  the  bone 
marrow  and,  in  some  case,  by  the  concomitant 
presence of an extramedullary involvement. Only 2% 
of MM cases are identified in patients younger than 40 
years.  To  the  best  of  our  knowledge,  there are  no 
reported cases of a MM diagnosed in patients with CF. 
However, a mismanagement of protein folding and 
function  during  membrane  trafficking  through  the 
exocytic  and  endocytic  cell  pathways  by  the 
proteostasis network is responsible for a wide range of 
diseases  that  include  lysosomal  storage  diseases, 
myelination  diseases,  CF,  systemic  amyloidosis  and 
light chain myeloma.
10
Bortezomib  is  the  first  clinically  approved 
proteasome inhibitor for patient with relapsed and/or 
refractory  MM.  His  effectiveness  was  established  in 
the phase III APEX
3 trial in terms of both response and 
time  to  progression  compared  to  high  dose 
dexamethasone.  Data  from  phase  II/III  trials  in 
untreated  MM  patients  confirmed  the  efficacy  and 
safety  of  Bortezomib  alone  or  in  combination  with 
other  antimyeloma  drugs.
11,12 Based  on  the 
consideration that patients with CF can present acute 
respiratory complications that are the most challenging 
problems and account for more than 90% of deaths in 
these patients,
13 we decided to use Bortezomib alone, 
in this young patient with CF who received a diagnosis 
of MM, in view of the heavily immunocompromized 
status of the patient and his history of frequent lung 
infection reactivations and Pseudomonas colonization. 
We obtained a marked and persistent response without 
important side effects, suggesting that Bortezomib can 
be  successfully  utilized  for  the  management  of  this 
difficult disease situation.
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